These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 37386901)

  • 1. Do quantitative levels of antispike-IgG antibodies aid in predicting protection from SARS-CoV-2 infection? Results from a longitudinal study in a police cohort.
    Sendi P; Widmer N; Branca M; Thierstein M; Büchi AE; Güntensperger D; Blum MR; Baldan R; Tinguely C; Heg D; Theel ES; Berbari E; Tande AJ; Endimiani A; Gowland P; Niederhauser C;
    J Med Virol; 2023 Jul; 95(7):e28904. PubMed ID: 37386901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel.
    Gilboa M; Gonen T; Barda N; Cohn S; Indenbaum V; Weiss-Ottolenghi Y; Amit S; Asraf K; Joseph G; Levin T; Kanaaneh Y; Aydenzon A; Canetti M; Freedman L; Zuckerman N; Mendelson E; Doolman R; Kreiss Y; Regev-Yochay G; Lustig Y
    JAMA Netw Open; 2023 May; 6(5):e2314757. PubMed ID: 37219906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
    Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
    Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients.
    Roy A; Saade C; Josset L; Clément B; Morfin F; Destras G; Valette M; Icard V; Billaud G; Oblette A; Debombourg M; Garrigou C; Brengel-Pesce K; Generenaz L; Saker K; Hernu R; Pozzetto B; Lina B; Trabaud MA; Trouillet-Assant S; Bal A
    J Med Virol; 2023 Aug; 95(8):e28984. PubMed ID: 37503561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
    Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
    JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study.
    Dinç HÖ; Demirci M; Özdemir YE; Sirekbasan S; Aktaş AN; Karaali R; Tuyji Tok Y; Özbey D; Akçin R; Gareayaghi N; Kuşkucu MA; Midilli K; Aygün G; Sarıbaş S; Kocazeybek B
    Balkan Med J; 2022 May; 39(3):172-177. PubMed ID: 35378574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study.
    Regev-Yochay G; Lustig Y; Joseph G; Gilboa M; Barda N; Gens I; Indenbaum V; Halpern O; Katz-Likvornik S; Levin T; Kanaaneh Y; Asraf K; Amit S; Rubin C; Ziv A; Koren R; Mandelboim M; Tokayer NH; Meltzer L; Doolman R; Mendelson E; Alroy-Preis S; Kreiss Y
    Lancet Microbe; 2023 May; 4(5):e309-e318. PubMed ID: 36963419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Infection during the Omicron Surge among Patients Receiving Dialysis: The Role of Circulating Receptor-Binding Domain Antibodies and Vaccine Doses.
    Montez-Rath ME; Garcia P; Han J; Cadden L; Hunsader P; Morgan C; Kerschmann R; Beyer P; Dittrich M; Block GA; Parsonnet J; Chertow GM; Anand S
    J Am Soc Nephrol; 2022 Oct; 33(10):1832-1839. PubMed ID: 35973733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed Kinetics of IgG, but Not IgA, Antispike Antibodies in Transplant Recipients following SARS-CoV-2 Infection.
    Cravedi P; Ahearn P; Wang L; Yalamarti T; Hartzell S; Azzi Y; Menon MC; Jain A; Billah M; Fernandez-Vina M; Gebel HM; Woodle ES; Haddad NS; Morrison-Porter A; Lee FE; Sanz I; Akalin E; Girnita A; Maltzman JS
    J Am Soc Nephrol; 2021 Dec; 32(12):3221-3230. PubMed ID: 34599041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
    Özgür D; Tütüncü EE
    Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
    Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
    Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection.
    Vangeti S; Periasamy S; Sun P; Balinsky CA; Mahajan AS; Kuzmina NA; Soares-Schanoski A; Cooper E; Beckett C; Marayag J; Marrone A; Nunez E; Ge Y; Porter CK; Goforth CW; Lizewski SE; Lizewski R; Jani V; Sugiharto VA; Schilling M; Yu XB; Marjanovic N; George MC; Bukreyev A; Sealfon SC; Letizia AG; Ramos I
    Microbiol Spectr; 2022 Dec; 10(6):e0183722. PubMed ID: 36374040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
    Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
    Front Immunol; 2022; 13():909910. PubMed ID: 35784321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses.
    Zens KD; Llanas-Cornejo D; Menges D; Fehr JS; Münz C; Puhan MA; Frei A
    Int J Infect Dis; 2023 Aug; 133():18-26. PubMed ID: 37149211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison.
    Kroidl I; Winter S; Rubio-Acero R; Bakuli A; Geldmacher C; Eser TM; Déak F; Horn S; Zielke A; Ahmed MIM; Diepers P; Guggenbühl J; Frese J; Bruger J; Puchinger K; Reich J; Falk P; Markgraf A; Fensterseifer H; Paunovic I; Thomschke A; Pritsch M; Riess F; Saathoff E; Hoelscher M; Olbrich L; Castelletti N; Wieser A;
    Virol J; 2023 Sep; 20(1):200. PubMed ID: 37658454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.